Old Web
English
Sign In
Acemap
>
authorDetail
>
Siti Rahmaputri
Siti Rahmaputri
University of California, San Francisco
Pathology
Medicine
in patient
Dinaciclib
Cyclin-dependent kinase 1
3
Papers
7
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).
2020
Journal of Clinical Oncology
Ozge Gumusay
Jonathan R. Renslo
Chiara A. Wabl
Amy Jo Chien
Michelle E. Melisko
Melanie Catherine Majure
Siti Rahmaputri
Mark M. Moasser
John W. Park
Hope S. Rugo
Show All
Source
Cite
Save
Citations (0)
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.
2020
Journal of Clinical Oncology
Amy Jo Chien
Amelia S Gliwa
Siti Rahmaputri
Heidi F Dittrich
Melanie Catherine Majure
Hope S. Rugo
Michelle E. Melisko
Pamela N. Munster
John W. Park
Mark M. Moasser
Mehrdad Matloubian
Tasha Lea
Julia Rohrberg
Gregor Krings
Andrei Goga
Show All
Source
Cite
Save
Citations (5)
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC).
2019
Journal of Clinical Oncology
Amy Jo Chien
Siti Rahmaputri
Heidi F Dittrich
Melanie Catherine Majure
Hope S. Rugo
Michelle E. Melisko
Andrei Goga
Show All
Source
Cite
Save
Citations (2)
1